The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients

Functional Neurology

Volumn 28, Issue 1, 2013, Pages 13-17

  Brusa, Livia ^a   Pavino, Valentina ^a   Massimetti, Maria Carla ^a   Bove, Raffaele ^a   Iani, Cesare ^a   Stanzion, Paolo ^b,c  

^a S EUGENIO HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Cabergoline; Cognition; Pharmacokinetic; Rotigotine

Indexed keywords

CABERGOLINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ROTIGOTINE; ANTIPARKINSON AGENT; BENZOTHIAZOLE DERIVATIVE; ERGOLINE DERIVATIVE; PERGOLIDE; PRAMIPEXOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; INTELLIGENCE TEST; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; NEUROPSYCHOLOGY; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; SEMANTICS; VERBAL BEHAVIOR; AGED; ATTENTION; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; EXECUTIVE FUNCTION; LEARNING; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PSYCHOLOGIC TEST; PSYCHOLOGICAL ASPECT;

AGED; ANTIPARKINSON AGENTS; ATTENTION; BENZOTHIAZOLES; COGNITION; CROSS-OVER STUDIES; DOPAMINE AGONISTS; ERGOLINES; EXECUTIVE FUNCTION; FEMALE; HUMANS; INTELLIGENCE TESTS; LEVODOPA; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PERGOLIDE; TRAIL MAKING TEST; VERBAL LEARNING;

MLCS; MLOWN;

EID: 84881253997     PISSN: 03935264     EISSN: 19713274     Source Type: Journal    
DOI: 10.11138/FNeur/2013.28.1.007     Document Type: Article

References (15)

1. Brusa L, Bassi A, Stefani A, et al (2003). Pramipexole in comparison to l-dopa: a neuropsychological study. J Neural Transm 110: 373-380.
2. Brusa L, Tiraboschi P, Koch G, et al (2005). Pergolide effect on cognitive functions in early-mild Parkinson's disease. J Neural Transm 112: 231-237.
3. Carlesimo GA, Caltagirone C, Gainotti G (1996). The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. Eur Neurol 36: 378-384.
4. Daniel SE, Lees AJ (1993). Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39: 165-172.
5. Fahn S, Elton RL, UPDRS Development Committee (1987). Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, et al. (Eds) Recent Developments in Parkinson's Disease. Florham Park, NY: MacMillan Healthcare Information, pp. 153-163, 293-304.
6. Gerlach M, Double K, Arzberger T, et al (2003). Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110: 1119-1127.
7. Granon S. Passetti F, Thomas KL, et al (2000). Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 2000; 20: 1208-1215.
8. Kehagia AA, Barker RA, Robbins TW (2010). Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in Parkinson's disease. Lancet Neurol 9: 1200-1213.
9. Krikorian R, Bartok J, Gay N (1994). Tower of London procedure: a standard method and developmental data. J Clin Exp Neuropsychol 16: 840-850.
10. Leiva-Santana C, Alvarez-Saúco M (2006). Levodopa and cognitive disorders in Parkinson's disease. Rev Neurol 43: 95-100.
11. Morrison CE, Borod JC, Brin MF, et al (2004). Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD). J Neural Transm 111:1333-1341.
12. Müller U, von Cramon Y, Pollmann S (1998). D1 versus D2 receptors modulation of visuospatial working memory in humans. J Neurosci 18: 2720-2728.
13. Naidu Y and Chaudhuri R (2007). Transdermal rotigotine: a new non-ergot dopamine agonist for treatment of Parkinson's disease. Expert Opin Drug Deliv 4:111-118.
14. Perachon S, Schwartz JC, Sokoloff P (1999). Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. Eur J Pharmacol 366: 293-300.
15. Pezze MA, Dalley JW, Robbins TW (2007). Differential roles of dopamine D1 and D2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task. Neuropsychopharmacology 32: 273-283.